Paul A Carpenter, MD, MBBS

Paul A Carpenter, MD, MBBS


  • Children's Title: Attending Physician, Pediatric Blood and Marrow Transplant, Cancer and Blood Disorders Center
  • Academic Title: Professor, Department of Pediatrics, University of Washington School of Medicine
  • Research Center: Ben Towne Center for Childhood Cancer Research
  • On Staff Since: June 1999
"One of the most rewarding aspects of my work is the privilege of forging long-term relationships with families who are faced with what must be one of the most challenging experiences of their lives caring for a child with a life-threatening disorder that is potentially treatable by stem cell transplantation. When I see patients, I try to listen attentively and maintain open communication. I focus on empowering patients and their families with evidence-based knowledge and offering them treatment options that focus on quality of life."
  • Biography

    Paul Carpenter, MD, is an attending physician at Seattle Children's Hospital, clinical director for long term follow-up clinical service at Fred Hutchinson Cancer Center and a professor at the University of Washington, with a focus on graft-versus-host disease (GVHD). He supervises junior attending staff on the pediatric hematopoietic cell transplant service at Fred Hutchinson. His local responsibilities include long-standing contributions to the Fred Hutchinson Standard Practice Committee and Standard Practice Manual.

    He chairs the American Society of Transplantation and Cellular Therapy's Committee on Practice Guidelines. His clinical and research interests focus on GVHD, which is the major and potentially lethal complication of hematopoietic cell transplant. His research continues to explore new therapies for the treatment of acute and chronic GVHD, and he is an active member in the national efforts to advance the field of chronic GVHD treatment. He is also interested in therapies designed to ameliorate key morbidities associated with chronic immunosuppressive therapies, such as bisphosphonate therapy for glucocorticoid-induced bone disease and the use of statins to treat hyperlipidemia. He has designed and participated in studies to evaluate the safety and efficacy of tyrosine kinase inhibitors as post-transplant therapy for high-risk Philadelphia chromosomepositive leukemias and for the treatment of chronic graft versus host disease. He was the principal investigator of the inaugural Blood and Marrow Clinical Trials Network (BMT CTN) Phase II/III 0801 trial for chronic graft-versus-host-disease.

    Board Certification(s)



    University of Sydney Faculty of Medicine, Sydney


    Royal Sydney Children's Hospital, Randwick


    Royal Sydney Children's Hospital, Randwick
    University of Washington School of Medicine, Seattle, WA

    Clinical Interests

    Graft vs. host disease

    Long-term follow-up after hematopoetic cell transplantation

  • Related Resources

  • Patient Testimonials

    • {{ testimonial.displayName }}
      {{ testimonial.location }}
      {{ formatTestimonialDate( }}

      {{ testimonial.testimony }}

  • Awards and Honors

    Award Name Award Description Awarded By Award Date
    {{ }} {{ award.description }} {{ award.organization }} {{ award.displayDate }}
  • Publications

  • Presentations

    Presentation Title Event Location Date
    {{ presentation.title }} {{ presentation.presentedAt }} {{ presentation.location }} {{ presentation.displayDate }}
  • Research Funding

    Grant Title Grantor Amount Award Date
    {{ funding.title }} {{ funding.grantedBy }} {{ funding.amount }} {{ funding.displayDate }}
  • Clinical Trials and Research Studies

    {{ item.t }}

    {{ }}

    {{ item.obj }}

    Condition: {{ item.con }} Phase: {{ }} ID: {{ item.nct }}

    No clinical trials found for Paul A Carpenter, MD, MBBS.